• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
  • Contact Us
Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge

Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge

by Annie De Groot | Sep 30, 2020

Immune engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge

Recent Posts

  • Save the Date: Artificial Intelligence / Human Intelligence Workshop 2025
  • Thinking Out Loud: October 2024
  • EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
  • The Amsterdam Immunogenicity and Tolerance Seminar: 2024
  • Thinking Out Loud: September 2024

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

Knowledge Base

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline